⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2018-08-16
Target enrollment:
Participant gender:
Summary
To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine
the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and
biodistribution of the probe; and to determine imaging parameters for optimal lymphoid and
tumor visualization.